Lo que siempre habiamos dicho, no hay contraindicacion absoluta de tratamientos concomitantes en pacientes con isotretinoina.

ASDS Releases Recommendations on Skin Procedures

Dermatol Surg; ePub 2017 May 10; Waldman, Bolotin, et al

May 24, 2017

The American Society for Dermatologic Surgery (ASDS) recently concluded that there is insufficient evidence to justify delaying treatment with superficial chemical peels and nonablative lasers, including hair removal lasers and lights, vascular lasers, and nonablative fractional devices for patients currently or recently exposed to isotretinoin (13-cis-retinoic acid). Superficial and focal dermabrasion may also be safe when performed by a well-trained clinician.

Currently, the isotretinoin package insert contains language advising the discontinuation of isotretinoin for 6 months before performing cosmetic procedures, including waxing, dermabrasion, chemical peels, laser procedures, or incisional and excisional cold-steel surgery. It is common practice to follow this standard because of concerns regarding reports of sporadic adverse events and increased risk of scarring.

In response, the ASDS developed a task force of content experts to review the evidence and provide guidance regarding the safety of skin procedures, including resurfacing, energy device treatments, and incisional and excisional procedures, in the setting of concurrent or recent isotretinoin use.  

Citation:

Waldman A, Bolotin D, Arndt KA, et al. ASDS Guidelines Task Force: Consensus recommendations regarding the safety of lasers, dermabrasion, chemical peels, energy devices, and skin surgery during and after isotretinoin use. [Published online ahead of print May 10, 2017]. Dermatol Surg. doi:10.1097/DSS.0000000000001166.